AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38134484 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block with 100 mg of ropivacaine
Number of subjects: 50
Study 38134484 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 50
Study 38134484 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block
Number of subjects: 50
Study 38134484 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block and Sciatic nerve block
Number of subjects: 50
Study 38134562 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 572
Study 38134562 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector-based vaccination
Number of subjects: 572
Study 38134562 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-based vaccination
Number of subjects: 572
Study 38134936 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9)
Number of subjects: 0
Study 38134936 — intervention group
Group type: EXPERIMENTAL
Intervention: Good expanders
Number of subjects: 0
Study 38134936 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor expanders
Number of subjects: 0
Study 38134948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus cisplatin-based chemotherapy
Number of subjects: 804
Study 38134948 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin-based chemotherapy
Number of subjects: 804
Study 38135005 — intervention group
Group type: EXPERIMENTAL
Intervention: MED-mushroom diet (1 serving/d of whole Agaricus bisporus and Pleurotus ostreatus mushrooms)
Number of subjects: 60
Study 38135005 — intervention group
Group type: COMPARATOR
Intervention: MED-control diet (without mushrooms)
Number of subjects: 60
Study 38135005 — intervention group
Group type: COMPARATOR
Intervention: MED diet (independent of mushroom consumption)
Number of subjects: 60
Study 38135059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis assessment at baseline
Number of subjects: 294
Study 38135173 — intervention group
Group type: EXPERIMENTAL
Intervention: PACIFIC ontology for data management
Number of subjects: 0
Study 38135184 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel + cisplatin + capecitabine as induction chemotherapy for three cycles
Number of subjects: 19
Study 38135187 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (Stereotactic MR-guided adaptive radiation therapy) delivered on a 0.35 T MR-guided system prescribed to 50 Gy in 5 fractions
Number of subjects: 136
Study 38135187 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (Stereotactic MR-guided adaptive radiation therapy)
Number of subjects: 136
Study 38135302 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaboratives (QIC)
Number of subjects: 0
Study 38135308 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress (caseness on HSCL-10 and PCL-5)
Number of subjects: 287
Study 38135308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 287
Study 38135308 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous symptoms of depression, fear of infection, and feeling of loneliness
Number of subjects: 287
Study 38135314 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular search for TB in stool samples with Xpert assay
Number of subjects: 0
Study 38135314 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of pulmonary TB signs on chest X-rays with CAD4TB technology
Number of subjects: 0
Study 38135320 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day of dark chocolate containing 500 mg total polyphenols and 100 mg vitamin E (n=25)
Number of subjects: 75
Study 38135320 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenol chocolate without additional vitamin E (n=25)
Number of subjects: 75
Study 38135320 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining baseline diet (n=25)
Number of subjects: 75
Study 38135320 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups will follow a similar physical exercise programme.
Number of subjects: 75
Study 38135329 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week self-care intervention
Number of subjects: 25
Study 38135333 — intervention group
Group type: EXPERIMENTAL
Intervention: in-hospital short-term PORT (education, inspiratory muscle training, active cycle of breathing techniques, early mobilisation)
Number of subjects: 800
Study 38135333 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 800
Study 38135359 — intervention group
Group type: EXPERIMENTAL
Intervention: HoloSNS for surgical planning using connectomic hypotheses
Number of subjects: 0
Study 38135359 — intervention group
Group type: COMPARATOR
Intervention: Traditional neurosurgical planning workstations
Number of subjects: 0
Study 38135369 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT (Hematopoietic Stem Cell Transplantation)
Number of subjects: 0
Study 38135371 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral decitabine-cedazuridine (35 mg decitabine and 100 mg cedazuridine once daily for 5 days)
Number of subjects: 133
Study 38135371 — intervention group
Group type: COMPARATOR
Intervention: Intravenous decitabine (20 mg/m2)
Number of subjects: 133
Study 38135371 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral decitabine-cedazuridine
Number of subjects: 133
Study 38135371 — intervention group
Group type: COMPARATOR
Intervention: Intravenous decitabine
Number of subjects: 133
Study 38135485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudexacianinium (ASP5354) 1.0 mg intravenous injection
Number of subjects: 0
Study 38135485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudexacianinium (ASP5354) 3.0 mg intravenous injection
Number of subjects: 0
Study 38135485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudexacianinium (ASP5354) 0.3 mg intravenous injection
Number of subjects: 0
Study 38135732 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRF-C
Number of subjects: 338
Study 38135732 — intervention group
Group type: COMPARATOR
Intervention: CVS-WL
Number of subjects: 338
Study 38137083 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery training
Number of subjects: 56
Study 38137083 — intervention group
Group type: COMPARATOR
Intervention: Control condition (resting quietly)
Number of subjects: 56
Study 38137533 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-oriented therapy
Number of subjects: 0
Study 38137669 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 35
Study 38137669 — intervention group
Group type: COMPARATOR
Intervention: 6-Mercaptopurine (6-MP)
Number of subjects: 35
Study 38140005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ped-TMZ oral suspension
Number of subjects: 36
Study 38140005 — intervention group
Group type: COMPARATOR
Intervention: TMZ capsules
Number of subjects: 36
Study 38140184 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 584
Study 38140184 — intervention group
Group type: COMPARATOR
Intervention: Baseline IgG levels ≥ 1.3 µg/mL
Number of subjects: 584
Study 38140184 — intervention group
Group type: COMPARATOR
Intervention: Baseline IgG levels < 1.3 µg/mL
Number of subjects: 584
Study 38140282 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month hypocaloric diet
Number of subjects: 0
Study 38140802 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability stage
Number of subjects: 631
Study 38140802 — intervention group
Group type: EXPERIMENTAL
Intervention: History of arrhythmic disorder
Number of subjects: 631
Study 38140802 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 631
Study 38140802 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on disability stage, arrhythmias, diabetes, and left ventricular systolic dysfunction
Number of subjects: 631
Study 38140854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous belimumab 10 mg/kg
Number of subjects: 100
Study 38140854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38141101 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCHF diet
Number of subjects: 91
Study 38141101 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 91
Study 38141101 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCHF + HIIT
Number of subjects: 91
Study 38141101 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 91
Study 38141138 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-containing multivitamin and mineral supplements (≥ 150 μg/day)
Number of subjects: 835
Study 38141138 — intervention group
Group type: COMPARATOR
Intervention: Non-users of iodine-containing supplements
Number of subjects: 835
Study 38141201 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity at Month 6
Number of subjects: 649
Study 38141201 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity at Month 6 (for patients with advanced cancer)
Number of subjects: 649
Study 38141201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep problems at baseline and Month 6
Number of subjects: 649
Study 38141201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-lagged associations for sleep and fatigue
Number of subjects: 649
Study 38141256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 20 mg
Number of subjects: 131
Study 38141256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 70 mg
Number of subjects: 131
Study 38141256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200 mg
Number of subjects: 131
Study 38141256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 38141496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand power (STS power)
Number of subjects: 86
Study 38141496 — intervention group
Group type: COMPARATOR
Intervention: Knee extensor maximal isometric strength (KE MVC)
Number of subjects: 86
Study 38141595 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ischemia modified albumin (IMA), biglycan, and decorin levels
Number of subjects: 51
Study 38141595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of IMA, decorin, and biglycan plus TVS CL measurement
Number of subjects: 51
Study 38141595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction of preterm delivery
Number of subjects: 51
Study 38141637 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (100 mg) continued
Number of subjects: 1494
Study 38141637 — intervention group
Group type: COMPARATOR
Intervention: Doravirine (100 mg) switched
Number of subjects: 1494
Study 38141637 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (100 mg) continued or switched
Number of subjects: 1494
Study 38141686 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-gauge fine-needle biopsy (FNB) needle
Number of subjects: 42
Study 38141686 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge fine-needle biopsy (FNB) Franseen tip needle
Number of subjects: 42
Study 38141723 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized FFR pullback pressure gradient (PPG) and wall shear stress (WSS) analyses
Number of subjects: 105
Study 38141723 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal coronary artery disease (CAD) identified by high PPG
Number of subjects: 105
Study 38141723 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse coronary artery disease (CAD)
Number of subjects: 105
Study 38141721 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma with 2 or more positive biomarkers
Number of subjects: 647
Study 38141721 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma with 1 positive biomarker
Number of subjects: 647
Study 38141721 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma with low blood EOS
Number of subjects: 647
Study 38141721 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma triple-negative
Number of subjects: 647
Study 38141721 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma overall
Number of subjects: 647
Study 38141721 — intervention group
Group type: COMPARATOR
Intervention: Controlled asthma
Number of subjects: 647
Study 38141879 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole breast radiotherapy (WBRT) after breast conserving surgery with sentinel lymph node biopsy (SLNB)
Number of subjects: 1461
Study 38141879 — intervention group
Group type: COMPARATOR
Intervention: Whole breast radiotherapy (WBRT) after breast conserving surgery without sentinel lymph node biopsy (no-SLNB)
Number of subjects: 1461
Study 38141879 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental axillary radiation therapy (RT) dose at axilla level I
Number of subjects: 1461
Study 38141879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour bed boost (yes)
Number of subjects: 1461
Study 38141879 — intervention group
Group type: COMPARATOR
Intervention: Tumour bed boost (no)
Number of subjects: 1461
Study 38142026 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training (PT)
Number of subjects: 30
Study 38142026 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rehabilitation (CR)
Number of subjects: 30
Study 38142044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (2 mg/kg/dose enterally every 12 hours for 7 days, 14 doses)
Number of subjects: 24
Study 38142044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 38142044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 24
Study 38142046 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment with Intensive Parental Coaching (IPC)
Number of subjects: 107
Study 38142046 — intervention group
Group type: COMPARATOR
Intervention: Family-Based Treatment (FBT)
Number of subjects: 107
Study 38142263 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network (NN) algorithm for predicting appendicular lean mass (ALM)
Number of subjects: 576
Study 38142448 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated white blood cell (WBC) count >11 × 10^9/L
Number of subjects: 2510
Study 38142448 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit level >45%
Number of subjects: 2510
Study 38142448 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC count >12 × 10^9/L (when hematocrit controlled at ≤45%)
Number of subjects: 2510
Study 38142605 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (n=26)
Number of subjects: 53
Study 38142605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=27)
Number of subjects: 53
Study 38142628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase
Number of subjects: 332
Study 38142628 — intervention group
Group type: COMPARATOR
Intervention: Sapropterin + MNT
Number of subjects: 332
Study 38142628 — intervention group
Group type: COMPARATOR
Intervention: MNT
Number of subjects: 332
Study 38142639 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid exposure in plasma and CSF
Number of subjects: 48
Study 38142660 — intervention group
Group type: EXPERIMENTAL
Intervention: Inline dynamometry
Number of subjects: 102
Study 38142695 — intervention group
Group type: EXPERIMENTAL
Intervention: Leterovir (480 mg once daily, adjusted to 240 mg for participants on cyclosporin A) for 200 days
Number of subjects: 220
Study 38142695 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 100 days
Number of subjects: 220
Study 38142697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 731
Study 38142697 — intervention group
Group type: COMPARATOR
Intervention: Standard optimal treatment alone (Control)
Number of subjects: 731
Study 38142697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) for OSA
Number of subjects: 731
Study 38142697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) for CSA
Number of subjects: 731
Study 38142702 — intervention group
Group type: EXPERIMENTAL
Intervention: dd-MVAC (every 2 weeks for a total of six cycles)
Number of subjects: 493
Study 38142702 — intervention group
Group type: COMPARATOR
Intervention: GC (every 3 weeks for a total of four cycles)
Number of subjects: 493
Study 38142801 — intervention group
Group type: EXPERIMENTAL
Intervention: Coalition members
Number of subjects: 1957
Study 38142801 — intervention group
Group type: COMPARATOR
Intervention: Residents
Number of subjects: 1957
Study 38142846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mim8 (denecimig)
Number of subjects: 42
Study 38142846 — intervention group
Group type: COMPARATOR
Intervention: Emicizumab (exploratory cohort)
Number of subjects: 42
Study 38142892 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine infusions (3 infusions over 11 days)
Number of subjects: 75
Study 38143014 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 39
Study 38143014 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS)
Number of subjects: 39
Study 38143014 — intervention group
Group type: COMPARATOR
Intervention: Comparison of VAS and NRS
Number of subjects: 39
Study 38143022 — intervention group
Group type: EXPERIMENTAL
Intervention: YRI+ENTR
Number of subjects: 1151
Study 38143022 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1151
Study 38143022 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTR
Number of subjects: 1151
Study 38143352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexican American individuals
Number of subjects: 1901
Study 38143352 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic white individuals
Number of subjects: 1901
Study 38143352 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1901
Study 38143352 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 1901
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfers (CCT)
Number of subjects: 1809
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS)
Number of subjects: 1809
Study 38143482 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1809
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator
Number of subjects: 1809
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT + SMS
Number of subjects: 1809
Study 38143482 — intervention group
Group type: COMPARATOR
Intervention: SOC-Outreach
Number of subjects: 1809
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing SMS
Number of subjects: 1809
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping SMS
Number of subjects: 1809
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing CCT
Number of subjects: 1809
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping CCT
Number of subjects: 1809
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial CCT escalated to navigator if lapse occurred
Number of subjects: 1809
Study 38143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial SMS escalated to navigator if lapse occurred
Number of subjects: 1809
Study 38143760 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD5 CAR-T cells
Number of subjects: 1
Study 38144428 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein supplementation (60 g)
Number of subjects: 122
Study 38144428 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein supplementation (20 g)
Number of subjects: 122
Study 38144428 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate placebo (PLA)
Number of subjects: 122
Study 38144428 — intervention group
Group type: COMPARATOR
Intervention: Dietary control (CON)
Number of subjects: 122
Study 38144487 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasix mesh
Number of subjects: 84
Study 38144515 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss and exercise program over 48 months
Number of subjects: 1230
Study 38144515 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1230
Study 38144529 — intervention group
Group type: EXPERIMENTAL
Intervention: belantamab mafodotin
Number of subjects: 111
Study 38145006 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive patients with taste disturbance
Number of subjects: 16
Study 38145006 — intervention group
Group type: COMPARATOR
Intervention: Negative controls (fungiform papillae from patients before March 2020)
Number of subjects: 16
Study 38145113 — intervention group
Group type: EXPERIMENTAL
Intervention: PyroHC (pyrotinib, trastuzumab, and chemotherapy)
Number of subjects: 135
Study 38145113 — intervention group
Group type: EXPERIMENTAL
Intervention: PyroHC (first-line treatment)
Number of subjects: 135
Study 38145113 — intervention group
Group type: EXPERIMENTAL
Intervention: PyroHC (in patients with brain metastases)
Number of subjects: 135
Study 38145113 — intervention group
Group type: EXPERIMENTAL
Intervention: PyroHC
Number of subjects: 135
Study 38145229 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training for cognitive behavioral therapy (CBT4CBT)
Number of subjects: 0
Study 38145229 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD)
Number of subjects: 0
Study 38145229 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 38145231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal AI system using ChatGPT and anterior segment images, smartphone-based, aiming for ≥90% sensitivity and ≥95% specificity for diagnosing and triaging ophthalmic diseases.
Number of subjects: 100
Study 38145231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal AI system using ChatGPT and anterior segment images, smartphone-based, validated across three locations.
Number of subjects: 100
Study 38145474 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive posterior spinal nonfusion (PSnF) surgery with bipolar one-way self-expanding rods (OWSER) system
Number of subjects: 14
Study 38145714 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary fiber (HFib) intervention with daily snacks high in dietary fiber (10-12 g/day) for 18 weeks.
Number of subjects: 0
Study 38145714 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study 38145715 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported dCBT intervention (SilverCloud)
Number of subjects: 426